Canadian Securities Exchange Welcomes Listing of DiagnosTear Technologies Inc
Canadian Securities Exchange Welcomes Listing of DiagnosTear Technologies Inc
Toronto, Ontario--(Newsfile Corp. - December 9, 2024) - The Canadian Securities Exchange ("CSE" or "the Exchange") today welcomed the listing of DiagnosTear Technologies Inc. ("DiagnosTear" or the "Company"). The Israel-based ophthalmic company recently completed an offering of subscription receipts, which converted into common shares and warrants prior to listing on the CSE. Its common shares were listed on the CSE today under the symbol DTR.
多倫多,安大略省--(Newsfile Corp. - 2024年12月9日)- 加拿大證券交易所("CSE"或"交易所")今天歡迎DiagnosTear科技有限公司("DiagnosTear"或"公司")上市。該以色列眼科公司最近完成了一次認購憑證的發行,該憑證在CSE上市前轉換爲普通股和Warrants。其普通股今天在CSE上市,標的爲DTR。
DiagnosTear is focused on the development and commercialization of disruptive diagnostic solutions for better management of eye diseases. The Company's TeaRx technology is a diagnostic platform intended for rapid, point-of-care testing of ophthalmic pathologies through tear fluid. The Company is currently developing products for the diagnosis of Dry Eye Disease and Red Eye causes.
DiagnosTear專注於開發和商業化顛覆性的診斷解決方案,以更好地管理眼病。公司的TeaRx技術是一個診斷平台,旨在通過淚液進行快速的現場檢測眼科病理。公司目前正在開發用於乾眼病和紅眼病因的診斷產品。
"The CSE has established itself as an ideal exchange for emerging companies advancing innovative technologies," said James Black, the CSE's Vice President, Listings Development. "We welcome DiagnosTear to the Exchange and wish the Company well with its exciting product development program."
"CSE已被確立爲推動創新技術的初創公司的理想交易所,"CSE副總裁、上市發展部的James Black說。"我們歡迎DiagnosTear加入交易所,並祝願公司在激動人心的產品開發計劃中取得成功。"
"We are excited about the commencement of trading on the CSE," said Yaacov Michlin, DiagnosTear's Chairman of the Board. "Building on our unique expertise in multi-parametric analysis of tear fluid, our efforts are focused on becoming a global leader in the development and commercialization of point-of-care diagnostic tools for ocular diseases like dry eye and red eye."
"我們對在CSE上開始交易感到興奮,"DiagnosTear董事會主席Yaacov Michlin說。"基於我們在淚液多參數分析方面的獨特專業知識,我們的努力專注於成爲全球眼科疾病(如干眼和紅眼)現場診斷工具開發和商業化的領導者。"
Dr. Shimon Gross, DiagnosTear's CEO, added: "Our solutions are non invasive, simple to perform and to interpret, and intended to allow healthcare providers to target the underlying cause of the disease and provide personalized treatment options."
DiagnosTear的首席執行官Dr. Shimon Gross補充道:"我們的解決方案是非侵入性的,操作簡單且易於解讀,旨在讓醫療提供者能夠針對疾病的根本原因並提供個性化治療方案。"
About the Canadian Securities Exchange:
加拿大證券交易所簡介:
The Canadian Securities Exchange is a rapidly growing exchange invested in working with entrepreneurs, innovators and disruptors to access public capital markets in Canada. The Exchange's efficient operating model, advanced technology and competitive fee structure help its listed issuers of all sectors and sizes minimize their cost of capital and enhance global liquidity.
加拿大證券交易所是一家快速增長的交易所,致力於與企業家、創新者和顛覆者合作,以進入加拿大的公共資本市場。交易所高效的運營模式、愛文思控股技術和具有競爭力的收費結構幫助其所有板塊和規模的上市公司降低資本成本並增強全球流動性。
Our client-centric approach and corresponding products and services ensure businesses have the support they need to confidently realize their vision.
我們的客戶導向方法及相應的產品和服務確保企業能夠獲得所需的支持,自信地實現他們的願景。
The CSE offers global investors access to an innovative collection of growing and mature companies.
CSE爲全球投資者提供進入不斷增長和成熟的公司創新集合的機會。
STAY CONNECTED WITH THE CSE
=============================
Website:
Blog:
CSE TV on YouTube:
CSE's "The Exchange for Entrepreneurs" Podcast:
Linkedin:
Twitter:
Instagram:
Facebook:
與CSE保持聯繫
=============================
網站:
博客:
CSE的YouTube頻道:
CSE的《創業者交易所》播客:
領英:
推特:
Instagram:
臉書:
Contact:
James Black
416-572-2000
james.black@thecse.com
聯繫:
詹姆斯·布萊克
416-572-2000
james.black@thecse.com